.png){kind=icon}
.png){kind=icon}
Return
More options, more questions in the management of early relapsed and/or refractory multiple myeloma
.png){kind=icon}
PRE
AI
C
S
DOI：10.1038/s41571-026-01191-6.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In MonumenTAL-3, the G-protein-coupled receptor class C group 5 memberD-directed bispecific T cell engager talquetamab combined with either daratumumab or daratumumab–pomalidomide conferred significantly longer progression-free survival than daratumumab–pomalidomide–dexamethasone in patients with relapsed and/or refractory multiple myeloma (≥1 prior line of therapy). These results herald a new therapeutic option for such patients but also raise questions regarding how talquetamab-based regimens should be integrated with B cell maturation antigen-directed T cell-redirecting therapies.
Journal
IF:
82.2
Papers:
2.3K
Citations:
3.3W
Organization
Cited Papers